Inter-American Development Bank
facebook
twitter
youtube
linkedin
instagram
Abierto al públicoBeyond BordersCaribbean Development TrendsCiudades SosteniblesEnergía para el FuturoEnfoque EducaciónFactor TrabajoGente SaludableGestión fiscalGobernarteIdeas MatterIdeas que CuentanIdeaçãoImpactoIndustrias CreativasLa Maleta AbiertaMoviliblogMás Allá de las FronterasNegocios SosteniblesPrimeros PasosPuntos sobre la iSeguridad CiudadanaSostenibilidadVolvamos a la fuente¿Y si hablamos de igualdad?Home
Citizen Security and Justice Creative Industries Development Effectiveness Early Childhood Development Education Energy Envirnment. Climate Change and Safeguards Fiscal policy and management Gender and Diversity Health Labor and pensions Open Knowledge Public management Science, Technology and Innovation  Trade and Regional Integration Urban Development and Housing Water and Sanitation
  • Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer

Ideas Matter

  • HOME
  • CATEGORIES
    • Behavioral Economics
    • Environment and Climate Change
    • Macroeconomics and Finance
    • Microeconomics and Competitiveness
    • Politics and Institutions
    • Social Issues
  • Authors
  • Spanish

Tackling Soaring Drug Prices in Latin America and the Caribbean

August 29, 2018 by Gianluca Cafagna - Diana Pinto 1 Comment


Faced with soaring drug prices, officials in the United States are taking on the pharmaceutical companies, desperate to stop the hemorrhage of up to thousands of dollars a month in family income towards prescription drugs. Individual states in just the last year have passed 37 drug laws, conscious that current trends are unsustainable.

But the United States is not alone in feeling the bite of rising prices. Latin America and the Caribbean also is caught in the rising spiral, where escalating drug costs deplete resources for expanding health access and improving health care quality. Indeed, the growth in pharmaceutical spending in Latin America and the Caribbean—at around 12% annually between 2013-2017—was four times faster than in North America and six times the rate in Europe.

Fragmented decision-making in Latin America and the Caribbean

As we indicate in an advance release of the IDB’s upcoming flagship report Better Spending for Better Lives, weak institutions and regulatory frameworks are largely to blame. Many countries in Europe have a centralized agency, like the National Institute for Clinical Excellence in the United Kingdom, that does technology assessments to determine which drugs are most cost-effective and which ones should be reimbursed with taxpayer money. In Latin America and the Caribbean, by contrast, this process is fragmented. A multiplicity of actors makes uncoordinated decisions in a wide range of areas so that there is little clarity for doctors, pharmacists and patients as to the safety and cost-effectiveness of drugs and the clinical guidelines for appropriate use.

Consider the widespread use of Ertapenem, an antibiotic used to treat in-hospital bacterial infections. Ertapenem is not on the World Health Organization’s list of essential medicines and is not recommended as a first-line of treatment.  There are much cheaper drugs with similar clinical effects. But because technology assessments and clinical practice guidelines for the drug have not been done in some countries, money is being wasted. Colombia, a country which has not engaged in either technology assessments or clinical guidelines, spends 16 times more per capita on the drug than Costa Rica and 12 times more than Peru, countries which, by contrast, have carried out at least some form of evaluation and use the drug much less. Another glaring example comes from the use of insulin glargine, an insulin analogue employed to treat diabetes. Its widespread use continues despite the fact that it can be up to 120% more expensive than human insulin, which provides similar benefits.

Generics could bring drug prices down

The failure to take advantage of generic drugs is another major problem.  Generics have the same effect as brand products and usually cost considerably less. But, unlike in Europe, Latin American and Caribbean countries use few financial and regulatory incentives to encourage their use. We looked at a sample of eight countries: Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, México and Peru. Among them, Colombia applies lower tariffs; Mexico offers tax exemptions and El Salvador financially supports technological upgrades in small- and medium-sized pharmaceutical companies that produce them. Yet in our sample these countries are exceptions. In some European countries, pharmacists have an obligation to tell their patients that a cheaper alternative to a medicine exists and may receive a bonus for selling a generic as opposed to a brand name drug. None of the countries in our sample, however, do this, and, in the process, lose out on the immense savings that generics have to offer.

A big benefit in centralized negotiating and purchasing of drugs

To their credit, several countries have figured out that centralized negotiation and purchasing of drugs can give governments better bargaining power with pharmaceutical companies, while eliminating the inefficiencies in low-scale purchasing that come when each health organization buys its own supplies. Some countries negotiated high-cost medications for cancer in large blocs through Mercosur or Unasur. And some compare the price of medicines in other countries and use this reference to establish their own price.

Still the overall picture is of a region that could make significant improvements towards better regulatory and financial incentives for using the most cost-effective drugs, while moving towards more rational drug prescribing and use. In health systems rife with excessive costs that affect the overall health of the citizenry, nearly half of the leading sources of inefficiencies are related to medicines. That shouldn’t be.


Filed Under: Macroeconomics and Finance, Politics and Institutions, Social Issues Tagged With: #Caribbean, #DrugPrices, #GenericDrugs, #LatAm, #medicines, #PrescriptionDrugs, DIA2018

Reader Interactions

Comments

  1. Rolando Villalaz Guerra says

    September 9, 2018 at 8:50 am

    Es un buen planteamiento para evitar el encarecimiento de medicamentos en America Latina. Lo que temo es que realmente el poder politico y economico de los grandes laboratorios permita estas opciones o alternativas que permitan lograr abaratar costos

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Follow Us

Subscribe

Search

Related posts

  • Boosting Efficiency En Route to Universal Health Coverage
  • Tougher Sentences: The Key to Fighting Crime in Latin America?
  • Banks and the Global Financial Crisis 10 Years On: Lessons from Latin America and the Caribbean
  • What Interactive Learning Can Teach Latin America
  • Boosting Global Innovation in Education

About this blog

The blog of the IDB's Research Department shares ideas that matter on public policy and development in Latin America and the Caribbean.

Footer

Banco Interamericano de Desarrollo
facebook
twitter
youtube
youtube
youtube

Blog posts written by Bank employees:

Copyright © Inter-American Development Bank ("IDB"). This work is licensed under a Creative Commons IGO 3.0 Attribution-NonCommercial-NoDerivatives. (CC-IGO 3.0 BY-NC-ND) license and may be reproduced with attribution to the IDB and for any non-commercial purpose. No derivative work is allowed. Any dispute related to the use of the works of the IDB that cannot be settled amicably shall be submitted to arbitration pursuant to the UNCITRAL rules. The use of the IDB's name for any purpose other than for attribution, and the use of IDB's logo shall be subject to a separate written license agreement between the IDB and the user and is not authorized as part of this CC- IGO license. Note that link provided above includes additional terms and conditions of the license.


For blogs written by external parties:

For questions concerning copyright for authors that are not IADB employees please complete the contact form for this blog.

The opinions expressed in this blog are those of the authors and do not necessarily reflect the views of the IDB, its Board of Directors, or the countries they represent.

Attribution: in addition to giving attribution to the respective author and copyright owner, as appropriate, we would appreciate if you could include a link that remits back the IDB Blogs website.



Privacy Policy

Copyright © 2023 · Magazine Pro on Genesis Framework · WordPress · Log in

Banco Interamericano de Desarrollo

Aviso Legal

Las opiniones expresadas en estos blogs son las de los autores y no necesariamente reflejan las opiniones del Banco Interamericano de Desarrollo, sus directivas, la Asamblea de Gobernadores o sus países miembros.

facebook
twitter
youtube
This site uses cookies to optimize functionality and give you the best possible experience. If you continue to navigate this website beyond this page, cookies will be placed on your browser.
To learn more about cookies, click here
X
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT